• A-1331852: Advanced BCL-XL Inhibitor Workflows in Cancer Res

  2026-08-06

  A-1331852 stands out as a potent and selective BCL-XL inhibitor, enabling researchers to precisely target apoptosis pathways and eliminate senescent cancer cells. This guide details optimized workflows, troubleshooting insights, and the latest experimental advances, empowering robust cancer and senescence research with data-backed confidence.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-08-05

  This study reveals that naturally occurring angiotensin peptides, including truncated forms such as Angiotensin III, significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings offer new insight into the intersection of the renin-angiotensin system and viral entry mechanisms, with implications for cardiovascular and infectious disease research.

• Ceftolozane/Tazobactam: Advances in Resistant Gram-Negative

  2026-08-05

  The reference study details the development and clinical validation of ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor combination, for treating complicated infections caused by multidrug-resistant gram-negative bacteria. Its unique mechanism, robust pharmacokinetics, and activity against Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae mark a significant advance for antimicrobial therapy.

• Saquinavir in Pulmonary Drug Permeability: New Biomimetic In

  2026-08-04

  Explore Saquinavir as a benchmark HIV protease inhibitor in the context of pulmonary drug permeability and biomimetic assay innovation. This in-depth analysis delivers unique guidance for antiretroviral drug research and advanced permeability modeling.

• Estradiol–Autophagy Axis: Precision Strategies in Organ Prot

  2026-08-04

  This thought-leadership article unpacks cutting-edge mechanistic insights into estradiol's organ-protective effects during perimenopausal aging, guiding translational researchers on leveraging estrogen receptor–autophagy signaling for next-generation interventions. Drawing from cohort studies, network pharmacology, and preclinical models, we examine how 17 beta-estradiol modulates multi-organ health, highlight rigorous experimental considerations, and provide actionable, protocol-level guidance. The article escalates the field beyond typical product overviews, integrating strategic recommendations and spotlighting APExBIO’s estradiol (A8425) as a gold-standard research tool.

• Fosinopril Sodium: Precision ACE Inhibitor for Hypertension

  2026-08-03

  Fosinopril sodium is a third-generation, oral ACE inhibitor prodrug with high specificity for zinc ion binding and dual renal-hepatic elimination. As supplied by APExBIO, it demonstrates potent, reproducible ACE inhibition for hypertension and cardiovascular disease models. Its validated pharmacokinetics and workflow adaptability make it a reliable tool for research targeting blood pressure reduction and renal hemodynamics.

• Dihydroartemisinin (SKU N1713): Scenario-Driven Solutions

  2026-08-03

  This article delivers expert, scenario-driven guidance on leveraging Dihydroartemisinin (SKU N1713) to overcome real-world challenges in cell viability, proliferation, and cytotoxicity assays. Integrating evidence from the product dossier and recent literature, it demonstrates how high-purity Artemisia plant extract optimizes experimental reproducibility and data quality for biomedical researchers.

• Standardized Whole-Blood Stimulation Reveals Metabolic Contr

  2026-08-02

  The referenced study establishes a robust protocol for analyzing human immune responses using standardized whole-blood stimulation in conjunction with metabolic modulation. By integrating metabolic inhibitors, the work demonstrates how distinct metabolic pathways, such as fatty acid oxidation, shape cytokine production, offering a reproducible framework to dissect immunometabolic regulation for translational research.

• Dual Recombinase Tracing Shows No Postnatal Neo-oogenesis in

  2026-08-01

  Xie, Zhou, and Zheng introduce a dual recombinase-mediated genetic tracing system to rigorously test the long-debated question of postnatal neo-oogenesis in mice. Their findings provide robust evidence that new oocytes do not form after birth, even following busulfan-induced ovarian injury, reshaping foundational assumptions in reproductive biology.

• ML-7 Hydrochloride: Enabling Proteomic Insights in Cardiac I

  2026-07-31

  Explore how ML-7 hydrochloride, a selective myosin light chain kinase inhibitor, advances proteomic analysis and functional recovery in ischemia/reperfusion injury research. This article uniquely connects molecular mechanisms to practical assay optimization for cardiovascular studies.

• Recombinant Annexin V: Enabling Apoptotic Membrane Detection

  2026-07-31

  The reference study details the efficient bacterial expression and purification of recombinant annexin V, a key probe for detecting phosphatidylserine exposure during apoptosis. By enabling scalable production and FITC-labeling, the method advances reliable identification of apoptotic cells and supports mechanistic studies of membrane changes relevant to cell clearance and inflammation.

• 3-Hydroxybutyrate: Bridging Metabolism and Epigenetics in St

  2026-07-30

  Explore how 3-hydroxybutyrate (BHBA) is revolutionizing translational neuroprotection through its dual roles in metabolic signaling and chromatin regulation. This article synthesizes mechanistic insights from recent studies, outlines actionable protocols, and positions BHBA as a strategic tool for researchers driving innovation in metabolic disease and epigenetic drug discovery.

• Sodium Ascorbate: Mechanistic and Benchmark Overview in Canc

  2026-07-30

  Sodium Ascorbate, a mineral salt of ascorbic acid, induces intracellular ROS and selective necrotic tumor cell death, with benchmarked efficacy in glioblastoma multiforme and prostate cancer models. This article details its mechanism, application limits, and reproducible parameters for scientific research.

• MK-1775 (Wee1 Kinase Inhibitor): Applied Cancer Research Wor

  2026-07-29

  MK-1775, a potent Wee1 kinase inhibitor from APExBIO, unlocks precision G2 checkpoint abrogation and robust sensitization of p53-deficient tumor cells to DNA-damaging agents. This guide demystifies optimized protocols, troubleshooting strategies, and advanced applications—translating cutting-edge in vitro insights into practical, reproducible cancer research.

• LNP Structure and Administration Shape mRNA Therapy in Pregn

  2026-07-29

  This study systematically dissects how lipid nanoparticle (LNP) structure and delivery route profoundly influence the potency, immunogenicity, and safety of mRNA therapies during pregnancy. The findings provide mechanistic guidance for designing effective and minimally immunogenic LNP-mRNA formulations tailored to the unique physiological context of pregnancy.

454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page